Currently, anti-PD1 inhibitors inhibit the interaction of PD-1 and PD-L1, thereby maintaining T cell activation and stimulating anti-cancer immunity (Boussiotis, 2016), achieving important clinical progress in certain patients with advanced or metastatic tumors (Topalian et al., 2020). Here, PDCD1 is linked to metastatic neoplasm.